The DYRK Family of Kinases in Cancer: Molecular Functions and Therapeutic Opportunities

Identification of cancer driver genes based on nucleotide context

(2020) Felix Dietlein et al.   NATURE GENETICS

Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases

(2020) Alejandro Correa-Sáez et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Impairment of DYRK2 by DNMT1‑mediated transcription augments carcinogenesis in human colorectal cancer

(2020) Tomotaka Kumamoto et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Screen identifies DYRK1B network as mediator of transcription repression on damaged chromatin

(2020) Chao Dong et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes

(2020) Martin Mehnert et al.   Nature Communications

Mapping the Human Kinome in Response to DNA Damage

(2019) Michel Owusu et al.   Cell Reports

Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence

(2019) Xiuhua Xu et al.   Cell Death & Disease

A complex between DYRK1A and DCAF7 phosphorylates the C-terminal domain of RNA polymerase II to promote myogenesis

(2019) Dan Yu et al.   NUCLEIC ACIDS RESEARCH

Design and Synthesis of a New Soluble Natural β-Carboline Derivative for Preclinical Study by Intravenous Injection

(2019) Sébastien Marx et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

DYRK1A regulates the recruitment of 53BP1 to the sites of DNA damage in part through interaction with RNF169

(2019) Vijay R. Menon et al.   CELL CYCLE

Dyrk3 loss activates the purine metabolism and promotes hepatocellular carcinoma progression

(2019) Fei Ma et al.   HEPATOLOGY

Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer

(2019) Shiho Yokoyama-Mashima et al.   CANCER LETTERS

p38 Stabilizes Snail by Suppressing DYRK2-Mediated Phosphorylation that is Required for GSK3β-βTrCP-Induced Snail Degradation

(2019) Ki-Jun Ryu et al.   CANCER RESEARCH

Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome

(2019) Juan Arranz et al.   NEUROBIOLOGY OF DISEASE

Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment

(2019) V. Deshmukh et al.   OSTEOARTHRITIS AND CARTILAGE

The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair

(2019) Steven E. Guard et al.   Scientific Reports

A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response

(2019) Julia Roewenstrunk et al.   Scientific Reports

Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus

(2019) Simone Granno et al.   Scientific Reports

KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells

(2019) Chun Shik Park et al.   BLOOD

Multiple functions of DYRK2 in cancer and tissue development

(2019) Saishu Yoshida et al.   FEBS LETTERS

DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291

(2019) Yang‐ling Li et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2

(2019) Rosario Morrugares et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression

(2019) Sourav Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization

(2019) Paul A. Allegretti et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma

(2018) Katie L. Uhl et al.   Cancer Cell International

Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer

(2018) Yoshimi Imawari et al.   CANCER SCIENCE

LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells

(2018) Yanmei Zou et al.   EUROPEAN JOURNAL OF CELL BIOLOGY

Dyrk2 mediated the release of proinflammatory cytokines in LPS-induced BV2 cells

(2018) Li Xu et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics

(2018) Dnyandev B. Jarhad et al.   JOURNAL OF MEDICINAL CHEMISTRY

Kinase inhibitors: the road ahead

(2018) Fleur M. Ferguson et al.   NATURE REVIEWS DRUG DISCOVERY

Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2

(2018) Sourav Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives

(2018) Fernanda Neumann et al.   Scientific Reports

DYRK1A Kinase Positively Regulates Angiogenic Responses in Endothelial Cells

(2018) Esteban J. Rozen et al.   Cell Reports

Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A

(2018) Thu Lan Nguyen et al.   Disease Models & Mechanisms

FBXW7: a critical tumor suppressor of human cancers

(2018) Chien-Hung Yeh et al.   Molecular Cancer

Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II

(2018) Huasong Lu et al.   NATURE

Kinase-controlled phase transition of membraneless organelles in mitosis

(2018) Arpan Kumar Rai et al.   NATURE

DYRK1A and cognition: A lifelong relationship

(2018) Maria L. Arbones et al.   PHARMACOLOGY & THERAPEUTICS

DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth

(2018) Jeroni Luna et al.   GUT

Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature

(2017) Thu Lan Nguyen et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy

(2017) Walter Becker   FEBS Journal

Interaction between RNF8 and DYRK2 is required for the recruitment of DNA repair molecules to DNA double-strand breaks

(2017) Takenori Yamamoto et al.   FEBS LETTERS

Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis

(2017) Yingying Chen et al.   HUMAN PATHOLOGY

Chemical screening identifies the β-Carboline alkaloid harmine to be synergistically lethal with doxorubicin

(2017) Reham Atteya et al.   MECHANISMS OF AGEING AND DEVELOPMENT

Regulation of Glioma Cells Migration by DYRK2

(2017) Yifen Shen et al.   NEUROCHEMICAL RESEARCH

A Requirement for Mena, an Actin Regulator, in Local mRNA Translation in Developing Neurons

(2017) Marina Vidaki et al.   NEURON

Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells

(2017) Hua Chen et al.   Oncotarget

Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells

(2016) Zhen Li et al.   CANCER LETTERS

Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways

(2016) Jongchan Kim et al.   CANCER RESEARCH

Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling

(2016) Susanne Hille et al.   CARDIOVASCULAR RESEARCH

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance

(2016) Richard Marcotte et al.   CELL

DYRK1A: A Promising Drug Target for Islet Transplant–Based Diabetes Therapies

(2016) Bengt-Frederik Belgardt et al.   DIABETES

A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition

(2016) Hyeongki Kim et al.   Disease Models & Mechanisms

Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial

(2016) Rafael de la Torre et al.   LANCET NEUROLOGY

The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome

(2016) P Lee et al.   LEUKEMIA

A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in Cancer Cell Dormancy

(2016) James MacDonald et al.   MOLECULAR CANCER RESEARCH

An ID2-dependent mechanism for VHL inactivation in cancer

(2016) Sang Bae Lee et al.   NATURE

Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer

(2016) R Mimoto et al.   ONCOGENE

Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma

(2016) Xiubing Zhang et al.   PATHOLOGY RESEARCH AND PRACTICE

DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway

(2016) Rajeev Singh et al.   Oncotarget

DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance

(2016) Wolfgang Gruber et al.   Oncotarget

A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma

(2016) Aneesha Radhakrishnan et al.   Scientific Reports

Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer

(2016) Haiyan Yan et al.   PLoS One

The adaptor protein DCAF7 mediates the interaction of the adenovirus E1A oncoprotein with the protein kinases DYRK1A and HIPK2

(2016) Florian Glenewinkel et al.   Scientific Reports

Bafilomycin A1 induces caspase-independent cell death in hepatocellular carcinoma cells via targeting of autophagy and MAPK pathways

(2016) Yumei Yan et al.   Scientific Reports

Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome

(2015) Anne L. Ashford et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Down-regulation of miR-1246 in cervical cancer tissues and its clinical significance

(2015) Y. Yang et al.   GYNECOLOGIC ONCOLOGY

Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma

(2015) Yuchan Wang et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3

(2015) Benjamin J. Thompson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Discovery and Optimization of a Novel Series of Dyrk1B Kinase Inhibitors To Explore a MEK Resistance Hypothesis

(2015) Jason G. Kettle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Chromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase

(2015) Chiara Di Vona et al.   MOLECULAR CELL

Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID

(2015) B W M van Bon et al.   MOLECULAR PSYCHIATRY

Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis

(2015) Xing Guo et al.   NATURE CELL BIOLOGY

The Expression of the Ubiquitin Ligase SIAH2 (Seven In Absentia Homolog 2) Is Increased in Human Lung Cancer

(2015) Paula Moreno et al.   PLoS One

DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma

(2015) Noriko Yamaguchi et al.   TUMOR BIOLOGY

Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1

(2015) Philipp Schneider et al.   Nature Communications

Novel harmine derivatives for tumor targeted therapy

(2015) Siwen Li et al.   Oncotarget

Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence

(2015) Na Zhou et al.   Oncotarget

Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy

(2015) Shunichiro Nomura et al.   BMC Urology

Stability of the human pregnane X receptor is regulated by E3 ligase UBR5 and serine/threonine kinase DYRK2

(2014) Su Sien Ong et al.   BIOCHEMICAL JOURNAL

Mirk/dyrk1B kinase is upregulated following inhibition of mTOR

(2014) Xiaobing Deng et al.   CARCINOGENESIS

The Down syndrome-related protein kinase DYRK1A phosphorylates p27Kip1and Cyclin D1 and induces cell cycle exit and neuronal differentiation

(2014) Ulf Soppa et al.   CELL CYCLE

A Form of the Metabolic Syndrome Associated with Mutations in DYRK1B

(2014) Ali R. Keramati et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Suppressor DYRK1A Effects on Proliferation and Chemoresistance of AML Cells by Downregulating c-Myc

(2014) Qiang Liu et al.   PLoS One

Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer

(2014) Yasuko Enomoto et al.   TUMOR BIOLOGY

Comparison of Cancer Cell Survival Triggered by Microtubule Damage after Turning Dyrk1B Kinase On and Off

(2013) Liwen Li et al.   ACS Chemical Biology

A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3β to phosphorylate cyclin D1 at Thr286, not Thr288

(2013) Anne L. Ashford et al.   BIOCHEMICAL JOURNAL

Mirk/Dyrk1B mediates G0/G1 to S phase cell cycle progression and cell survival involving MAPK/ERK signaling in human cancer cells

(2013) Jingchun Gao et al.   Cancer Cell International

DYRK2 controls the epithelial–mesenchymal transition in breast cancer by degrading Snail

(2013) Rei Mimoto et al.   CANCER LETTERS

The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis

(2013) S. Boichuk et al.   CANCER RESEARCH

Dual Specificity Kinase DYRK3 Couples Stress Granule Condensation/Dissolution to mTORC1 Signaling

(2013) Frank Wippich et al.   CELL

Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome

(2013) Teresa Davoli et al.   CELL

Lapatinib induces p27Kip1-dependent G₁ arrest through both transcriptional and post-translational mechanisms

(2013) Lin Tang et al.   CELL CYCLE

Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer

(2013) S. J. Davis et al.   CLINICAL CANCER RESEARCH

Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation

(2013) Hae-Yun Jung et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

(2013) Natividad Pozo et al.   JOURNAL OF CLINICAL INVESTIGATION

Functional Similarity between E6 Proteins of Cutaneous Human Papillomaviruses and the Adenovirus E1A Tumor-Restraining Module

(2013) M. Kuppuswamy et al.   JOURNAL OF VIROLOGY

Dosage of Dyrk1a Shifts Cells within a p21-Cyclin D1 Signaling Map to Control the Decision to Enter the Cell Cycle

(2013) Jia-Yun Chen et al.   MOLECULAR CELL

Exome Sequencing Identifies Early Gastric Carcinoma as an Early Stage of Advanced Gastric Cancer

(2013) Guhyun Kang et al.   PLoS One

Structures of Down Syndrome Kinases, DYRKs, Reveal Mechanisms of Kinase Activation and Substrate Recognition

(2013) Meera Soundararajan et al.   STRUCTURE

Harmine induces apoptosis in HepG2 cells via mitochondrial signaling pathway

(2012) Ming-Rong Cao et al.   Hepatobiliary & Pancreatic Diseases International

Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition

(2012) Jing Hu et al.   INTERNATIONAL JOURNAL OF CANCER

Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway

(2012) J. Y. Hong et al.   JOURNAL OF CELL SCIENCE

Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome

(2012) Sébastien Malinge et al.   JOURNAL OF CLINICAL INVESTIGATION

DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells

(2012) Naoe Taira et al.   JOURNAL OF CLINICAL INVESTIGATION

Novel Trisubstituted Harmine Derivatives with Original in Vitro Anticancer Activity

(2012) Raphaël Frédérick et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mutual regulation between SIAH2 and DYRK2 controls hypoxic and genotoxic signaling pathways

(2012) Moisés Pérez et al.   Journal of Molecular Cell Biology

Wnt Signaling Orchestration with a Small Molecule DYRK Inhibitor Provides Long-Term Xeno-Free Human Pluripotent Cell Expansion

(2012) Kouichi Hasegawa et al.   Stem Cells Translational Medicine

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

p53 downregulates Down syndrome-associated DYRK1A through miR-1246

(2011) Yu Zhang et al.   EMBO REPORTS

A kinase shRNA screen links LATS2 and the pRB tumor suppressor

(2011) K. Tschop et al.   GENES & DEVELOPMENT

DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly

(2011) L. Litovchick et al.   GENES & DEVELOPMENT

The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer

(2011) Jingchun Gao   INTERNATIONAL JOURNAL OF ONCOLOGY

Inactivation of Mirk/Dyrk1b Kinase Targets Quiescent Pancreatic Cancer Cells

(2011) D. Z. Ewton et al.   MOLECULAR CANCER THERAPEUTICS

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells

(2010) Jingchun Gao et al.   CANCER BIOLOGY & THERAPY

Regulated Segregation of Kinase Dyrk1A during Asymmetric Neural Stem Cell Division Is Critical for EGFR-Mediated Biased Signaling

(2010) Sacri R. Ferron et al.   Cell Stem Cell

DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles

(2010) Sergi Aranda et al.   FASEB JOURNAL

Transient arrest in a quiescent state allows ovarian cancer cells to survive suboptimal growth conditions and is mediated by both Mirk/dyrk1b and p130/Rb2

(2010) Jing Hu et al.   INTERNATIONAL JOURNAL OF CANCER

Splice Variants of the Dual Specificity Tyrosine Phosphorylation-regulated Kinase 4 (DYRK4) Differ in Their Subcellular Localization and Catalytic Activity

(2010) Chrisovalantis Papadopoulos et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

DYRK1A and DYRK3 Promote Cell Survival through Phosphorylation and Activation of SIRT1

(2010) Xiumei Guo et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Dyrk1A Phosphorylates p53 and Inhibits Proliferation of Embryonic Neuronal Cells

(2010) Joongkyu Park et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Adenovirus Type 5 E1A and E6 Proteins of Low-Risk Cutaneous Beta-Human Papillomaviruses Suppress Cell Transformation through Interaction with FOXK1/K2 Transcription Factors

(2010) J. Komorek et al.   JOURNAL OF VIROLOGY

MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling

(2010) Paula A. da Costa Martins et al.   NATURE CELL BIOLOGY

DYRK1B-dependent autocrine-to-paracrine shift of Hedgehog signaling by mutant RAS

(2010) Matthias Lauth et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Exploring the Link between Germline and Somatic Genetic Alterations in Breast Carcinogenesis

(2010) Núria Bonifaci et al.   PLoS One

Characterization of a Domain That Transiently Converts Class 2 DYRKs into Intramolecular Tyrosine Kinases

(2010) R. Kinstrie et al.   Science Signaling

Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A

(2010) Yasushi Ogawa et al.   Nature Communications

Mirk/Dyrk1B Maintains the Viability of Quiescent Pancreatic Cancer Cells by Reducing Levels of Reactive Oxygen Species

(2009) X. Deng et al.   CANCER RESEARCH

The kinase Mirk is a potential therapeutic target in osteosarcoma

(2009) C. Yang et al.   CARCINOGENESIS

Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation

(2009) Nora Göckler et al.   FEBS Journal

Mirk Regulates the Exit of Colon Cancer Cells from Quiescence

(2009) Kideok Jin et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

ATM Augments Nuclear Stabilization of DYRK2 by Inhibiting MDM2 in the Apoptotic Response to DNA Damage

(2009) Naoe Taira et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A

(2009) J. Fernandez-Martinez et al.   JOURNAL OF CELL SCIENCE

Expression of dual-specificity tyrosine-(Y)-phosphorylation–regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma

(2009) Shin-ichi Yamashita et al.   JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY

Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1

(2009) Kwan-Hyuck Baek et al.   NATURE

Protein kinase DYRK2 is a scaffold that facilitates assembly of an E3 ligase

(2009) Subbareddy Maddika et al.   NATURE CELL BIOLOGY

DYRK1A-Dosage Imbalance Perturbs NRSF/REST Levels, Deregulating Pluripotency and Embryonic Stem Cell Fate in Down Syndrome

(2008) Claudia Canzonetta et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Application of Active and Kinase-Deficient Kinome Collection for Identification of Kinases Regulating Hedgehog Signaling

(2008) Markku Varjosalo et al.   CELL

DYRK1A stabilizes HPV16E7 oncoprotein through phosphorylation of the threonine 5 and threonine 7 residues☆

(2008) Yuh-Jin Liang et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon

(2008) Antoine Italiano et al.   INTERNATIONAL JOURNAL OF CANCER

A quantitative analysis of kinase inhibitor selectivity

(2008) Mazen W Karaman et al.   NATURE BIOTECHNOLOGY

Chromosomal changes in high- and low-invasive mouse lung adenocarcinoma cell strains derived from early passage mouse lung adenocarcinoma cell strains

(2008) Linda M. Sargent et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY